ArticleLife (Basel, Switzerland)2026
Young Age Is Associated with Improved Survival After Resection of Non-Metastatic Pancreatic Ductal Adenocarcinoma.
Ingrid Garajová, Bing Wang, Inna Markovna Chen, Carsten Palnæs Hansen, Annalisa Comandatore, Nina Fokter Dovnik, Radim Nemecek, Michal Eid, Marko Hojnik, Damjan Sisinger and 6 more
Abstract read
In one paragraphArticle in Life (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
16 authors.
Bing WangLaboratory Medical Oncology, Department of Medical Oncology, Cancer Center Amsterdam, Amsterdam University Medical Center, Vrije Universiteit Amsterdam, 1081 HV Amsterdam, The Netherlands.ORCID 0009-0004-8086-7110 Inna Markovna ChenDepartment of Oncology, Copenhagen University Hospital-Herlev and Gentofte Hospital, 2730 Copenhagen, Denmark.ORCID 0000-0003-2891-0762 Carsten Palnæs HansenDepartment of Surgery and Transplantation, Rigshospitalet, Copenhagen University Hospital, 2100 Copenhagen, Denmark.ORCID 0000-0002-9256-2240 Annalisa ComandatoreGeneral Surgery Unit, Department of Translational Research and New Technologies in Medicine and Surgery, University of Pisa, 56126 Pisa, Italy.ORCID 0000-0001-6930-0595 Nina Fokter DovnikDepartment of Medical Oncology, University Medical Centre Maribor, 2000 Maribor, Slovenia.ORCID 0000-0002-5979-1404 Radim NemecekDepartment of Comprehensive Cancer Care, Masaryk Memorial Cancer Institute and Faculty of Medicine, Masaryk University, 65653 Brno, Czech Republic.ORCID 0000-0001-6825-0960 Michal EidDepartment of Internal Medicine, Hematology and Oncology, University Hospital Brno, Faculty of Medicine, Masaryk University, 62500 Brno, Czech Republic.ORCID 0000-0002-4433-5326 Marko HojnikDepartment of Pathology, University Medical Centre Maribor, 2000 Maribor, Slovenia.
Damjan SisingerDepartment of Pathology, University Medical Centre Maribor, 2000 Maribor, Slovenia.
Tomaž RojkoDepartment of Pathology, University Medical Centre Maribor, 2000 Maribor, Slovenia.
Fabio GelsominoDepartment of Oncology and Hematology, University Hospital of Modena, 41124 Modena, Italy.ORCID 0000-0001-7979-4795 Stefania De LorenzoOncology Unit, Azienda USL Bologna, 40124 Bologna, Italy.
Geert KazemierDepartment of Surgery, Amsterdam UMC, University of Amsterdam, 1105 AZ Amsterdam, The Netherlands.
Luca MorelliGeneral Surgery Unit, Department of Translational Research and New Technologies in Medicine and Surgery, University of Pisa, 56126 Pisa, Italy.ORCID 0000-0002-7742-9556 Elisa GiovannettiLaboratory Medical Oncology, Department of Medical Oncology, Cancer Center Amsterdam, Amsterdam University Medical Center, Vrije Universiteit Amsterdam, 1081 HV Amsterdam, The Netherlands.ORCID 0000-0002-7565-7504 Funding
European Organisation for Research and Treatment of Cancer RP-2146
6 · The paper itselfAbstract
In pancreatic ductal adenocarcinoma (PDAC), clinicians often ask whether young age is associated with more aggressive disease or patients more likely to tolerate curative-intent multimodality treatment. The prognostic meaning of age after surgery remains uncertain. We analyzed a retrospective multicenter surgical cohort of patients with resected non-metastatic PDAC. Candidate clinical variables were evaluated in univariable Cox models. The prespecified primary multivariable model included age, sex, N status, T stage, and CA19-9 status. Adjuvant therapy was evaluated in a sensitivity model. The cohort included 696 surgical patients; 70 (10.1%) were aged < 55 years. Median overall survival was 34.4 months in patients aged < 55 years versus 22.0 months in those aged ≥ 55 years (log-rank
Indexed as
ageCA19-9early-onset pancreatic canceroverall survivalpancreatic ductal adenocarcinomaprognosissurgery
Identifiers
PMID42795364
PMCPMC13608593
What OpenQuestion holds
Textmetadata
Read underepoch 390